BRPI0411679A - agente para inibição da reprodução de vìrus na membrana, método para a produção da mesma, composição farmacêutica e método para inibição da infecção viral - Google Patents

agente para inibição da reprodução de vìrus na membrana, método para a produção da mesma, composição farmacêutica e método para inibição da infecção viral

Info

Publication number
BRPI0411679A
BRPI0411679A BRPI0411679-8A BRPI0411679A BRPI0411679A BR PI0411679 A BRPI0411679 A BR PI0411679A BR PI0411679 A BRPI0411679 A BR PI0411679A BR PI0411679 A BRPI0411679 A BR PI0411679A
Authority
BR
Brazil
Prior art keywords
virus
inhibiting
membrane
agent
viral infection
Prior art date
Application number
BRPI0411679-8A
Other languages
English (en)
Inventor
Lev Davidovich Rasnetsov
Iakov Yudelevich Shvartsman
Irina Konstantinovna Lyalina
Betti Efimovna Rasnetsova
Original Assignee
Lev Davidovich Rasnetsov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lev Davidovich Rasnetsov filed Critical Lev Davidovich Rasnetsov
Publication of BRPI0411679A publication Critical patent/BRPI0411679A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"AGENTE PARA INIBIçãO DA REPRODUçãO DE VìRUS NA MEMBRANA, MéTODO PARA A PRODUçãO DA MESMA, COMPOSIçãO FARMACêUTICA E MéTODO PARA INIBIçãO DA INFECçãO VIRAL". A presente invenção se refere à indústria farmacêutica e mais especificamente ao fornecimento de um agente para a inibição da replicação de vírus na membrana, o objeto da invenção é fornecer um agente com base nos anions policarboxílicos de fulereno para a supressão da atividade dos vírus nas membranas no tratamento de doenças causadas por esses vírus; para realizar o referido objetivo, foi proposto um grupo de invenções reunidas por um conceito inventivo em comum, o referido grupo compreende um método para preparar compostos, estudando os mecanismos de ação, provisão de composições farmacêuticas e desenvolvimento de métodos de tratamento com seu uso; o referido objeto é obtido através da seleção de razões quantitativas dos componentes e das condições de reação, as quais garantem o preparado dos produtos de poliadição; estabeleceu-se que ao conduzir a síntese, a quantia de aminoácidos deve exceder a quantia de fulereno em mais de 50 vezes; o produto preparado pelo método proposto possui uma solubilidade ilimitada na água, biodisponibilidade necessária, alta eficácia de ação nas células não-infectadas, baixa toxicidade; o conteúdo da principal substância no produto alvo é de pelo menos 90%; o processo é adaptável à produção em linha de fluxo e pode ser utilizado na indústria farmacêutica; composições de drogas e métodos de tratamento de doenças infecciosas causadas pelo vírus da imunodeficiência humana (HIV), vírus do herpes simplex (HSC) e vírus da hepatite C (HCV) foram desenvolvidos
BRPI0411679-8A 2003-06-23 2004-05-31 agente para inibição da reprodução de vìrus na membrana, método para a produção da mesma, composição farmacêutica e método para inibição da infecção viral BRPI0411679A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2003118500/15A RU2236852C1 (ru) 2003-06-23 2003-06-23 Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
PCT/RU2004/000208 WO2004112804A1 (fr) 2003-06-23 2004-05-31 Agent d'inhibition de la reproduction de virus a membrane, procede de production dudit agent, composition pharmaceutique et methode d'inhibition des infections virales

Publications (1)

Publication Number Publication Date
BRPI0411679A true BRPI0411679A (pt) 2006-08-29

Family

ID=33434013

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411679-8A BRPI0411679A (pt) 2003-06-23 2004-05-31 agente para inibição da reprodução de vìrus na membrana, método para a produção da mesma, composição farmacêutica e método para inibição da infecção viral

Country Status (15)

Country Link
US (1) US20060122276A1 (pt)
EP (1) EP1645279A4 (pt)
JP (1) JP2007522082A (pt)
KR (1) KR20060017887A (pt)
CN (1) CN1819834A (pt)
AP (1) AP2006003495A0 (pt)
AU (1) AU2004249090A1 (pt)
BR (1) BRPI0411679A (pt)
CA (1) CA2530004A1 (pt)
EA (1) EA010483B1 (pt)
GE (1) GEP20084377B (pt)
IL (1) IL172634A0 (pt)
RU (1) RU2236852C1 (pt)
UA (1) UA82528C2 (pt)
WO (1) WO2004112804A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006160664A (ja) * 2004-12-07 2006-06-22 Vitamin C60 Bioresearch Kk フリーラジカル疾患予防治療用組成物
RU2462473C2 (ru) * 2007-06-19 2012-09-27 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) Полифункциональные аминокислотные производные фуллерена c60
CA2687557A1 (en) * 2007-06-19 2008-12-31 Institute Of Problems Of Chemical Physics Ras (Ipcp Ras) Polyfunctional fullerene c60 amino acid derivatives
AP3010A (en) * 2007-10-29 2014-10-31 Cipla Ltd Novel antiretroviral combination
RU2458914C1 (ru) * 2011-02-01 2012-08-20 Лев Давидович Раснецов Гомо- и гетеро-полиаминокислотные производные фуллерена c60, способ их получения и фармацевтические композиции на их основе
RU2458046C1 (ru) * 2011-02-01 2012-08-10 Лев Давидович Раснецов Гидратированные n-фуллерен-аминокислоты, способ их получения и фармацевтические композиции на их основе
RU2477273C2 (ru) 2011-03-30 2013-03-10 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) Серосодержащие производные фуллеренов и способ их получения
RU2501785C2 (ru) * 2011-08-30 2013-12-20 Федеральное государственное бюджетное учреждение науки Институт проблем химической физики Российской академии наук Применение пентааминофуллеренов в качестве противомикробных средств и противомикробная композиция на их основе
CN103347848B (zh) * 2012-02-06 2016-09-21 列夫·达维多维奇·拉斯涅特索夫 水合n-富勒烯氨基酸、其制备方法和以它为基础的药物组合物
CN103347849B (zh) * 2012-02-06 2016-05-11 列夫·达维多维奇·拉斯涅特索夫 富勒烯с60的均聚氨基酸和杂多氨基酸衍生物、其制备方法和基于该衍生物的药物组合物
RU2533232C2 (ru) * 2012-07-20 2014-11-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вирусологии им. Д.И. Ивановского" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "НИИ вирусологии им. Д.И. Ивановского" Минздравсоцразвития России Применение поликарбоксильного производного фуллерена в качестве микробицидного противовирусного средства
CN103705388A (zh) * 2013-12-19 2014-04-09 深圳市通产丽星股份有限公司 一种富勒烯胶囊及其应用
CN111135188A (zh) * 2018-11-06 2020-05-12 海南森溪海科技有限公司 富勒烯和/或其水溶性衍生物在预防和治疗女性生殖道疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5811460A (en) * 1994-01-24 1998-09-22 The Regents Of The University Of California Water soluble fullerenes with antiviral activity
US5648523A (en) * 1995-10-26 1997-07-15 Chiang Long Y Fullerene derivatives as free-radical scavengers
RU2124022C1 (ru) * 1997-04-10 1998-12-27 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Фуллереновое производное гликопептида, обладающее адъювантной активностью
US20030027870A1 (en) * 2001-05-15 2003-02-06 Wilson Stephen R. Fullerene derivatives that modulate nitric oxide synthase and clamodulin activity
RU2196602C1 (ru) * 2002-01-22 2003-01-20 Закрытое акционерное общество "ДЕСКО" Средство для ингибирования вич и цмв-инфекций и способ их ингибирования

Also Published As

Publication number Publication date
KR20060017887A (ko) 2006-02-27
US20060122276A1 (en) 2006-06-08
GEP20084377B (en) 2008-05-27
AP2006003495A0 (en) 2006-02-28
JP2007522082A (ja) 2007-08-09
EA010483B1 (ru) 2008-10-30
EP1645279A4 (en) 2009-10-21
EA200600010A1 (ru) 2006-06-30
CN1819834A (zh) 2006-08-16
AU2004249090A1 (en) 2004-12-29
CA2530004A1 (en) 2004-12-29
RU2236852C1 (ru) 2004-09-27
UA82528C2 (uk) 2008-04-25
IL172634A0 (en) 2006-04-10
EP1645279A1 (en) 2006-04-12
WO2004112804A1 (fr) 2004-12-29

Similar Documents

Publication Publication Date Title
BRPI0411679A (pt) agente para inibição da reprodução de vìrus na membrana, método para a produção da mesma, composição farmacêutica e método para inibição da infecção viral
WO1994019012A3 (en) Compositions and methods of application of reactive antiviral polymers
EP0427247B1 (de) Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
AU764592B2 (en) Methods and compositions for the selective modification of nucleic acids
BR0210350A (pt) Nucleosìdeos 4'-substituìdos
DK169657B1 (da) Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider
EP0601164A1 (en) Methods for treating viral infections
CN111135184A (zh) GS-441524在制备新型冠状病毒SARS-CoV-2抑制剂中的应用
BR9912142A (pt) 6-benzil-4-oxipirimidinas substituìdas, processopara sua preparação e composições contendo-as
JP2007515389A (ja) テクトリゲニンのイソフラボン誘導体、その調製、および有効成分としてこれを含む抗ウィルス剤
BR0107912A (pt) Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus
MX2008006545A (es) Sales del acido 9-oxoacridine-10-acetico con 1-alkilamino-1-desoxi -poliols.
EA015132B1 (ru) Лекарственное средство для лечения вирусных инфекций
CN101068540B (zh) 抗病毒性和免疫刺激性海鱼油组合物
WO1992002530A1 (en) Hexa-n-(o-hydroxybenzyl) neomycin b for inhibiting human retroviruses and for the treatment of aids
WO1991003242A1 (fr) Medicament antiviral
Tilles Antiviral agents
CN111135166A (zh) 一种由gc376与gs-441524组成的药物组合物及其抑制新冠病毒的用途
US6352695B1 (en) Methods and compositions for the selective modification of nucleic acids
US5254587A (en) Methods for treating AIDS
JPH05238939A (ja) 肝炎治療剤
Liebhaber et al. STUDIES OF A MYXOVIRUS RECOVERED FROM PATIENTS WITH INFECTIOUS HEPATITIS: I. ISOLATION AND CHARACTERIZATION
CN106928063A (zh) 巨大戟二萜醇类化合物及其在抗hiv潜伏治疗上的应用
CN101190935B (zh) 用于病毒性感染的化合物
Khanna et al. Convalescent plasma therapy for coronavirus in critically ill patients

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.